

Stephane Champiat

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2749715/publications.pdf>

Version: 2024-02-01

53
papers

6,848
citations

218381

26
h-index

168136

53
g-index

58
all docs

58
docs citations

58
times ranked

9742
citing authors

#	ARTICLE	IF	CITATIONS
1	Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. <i>Clinical Cancer Research</i> , 2017, 23, 1920-1928.	3.2	960
2	Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 473-486.	12.5	831
3	A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. <i>Lancet Oncology</i> , The, 2018, 19, 1180-1191.	5.1	811
4	Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. <i>JAMA Oncology</i> , 2018, 4, 1543.	3.4	567
5	Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab. <i>JAMA Dermatology</i> , 2016, 152, 45.	2.0	539
6	Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. <i>Journal of Hepatology</i> , 2018, 68, 1181-1190.	1.8	372
7	Hyperprogressive disease: recognizing a novel pattern to improve patient management. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 748-762.	12.5	304
8	Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer. <i>JAMA Oncology</i> , 2019, 5, 1310.	3.4	268
9	Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. <i>European Journal of Cancer</i> , 2018, 91, 21-29.	1.3	222
10	Intratumoural administration and tumour tissue targeting of cancer immunotherapies. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 558-576.	12.5	202
11	Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. <i>Lancet Haematology</i> , the, 2019, 6, e48-e57.	2.2	195
12	Exomics and immunogenics. <i>Oncolmmunology</i> , 2014, 3, e27817.	2.1	178
13	Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio-Oncology Guidelines. <i>Journal of the American Heart Association</i> , 2020, 9, e018403.	1.6	149
14	Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis. <i>European Journal of Cancer</i> , 2017, 82, 34-44.	1.3	146
15	Renal toxicities associated with pembrolizumab. <i>CKJ: Clinical Kidney Journal</i> , 2019, 12, 81-88.	1.4	101
16	Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation. <i>Clinical Cancer Research</i> , 2019, 25, 946-956.	3.2	96
17	Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1. <i>European Journal of Cancer</i> , 2018, 96, 91-104.	1.3	94
18	The development of immunotherapy in older adults: New treatments, new toxicities?. <i>Journal of Geriatric Oncology</i> , 2016, 7, 325-333.	0.5	93

#	ARTICLE	IF	CITATIONS
19	Incorporating Immune-Checkpoint Inhibitors into Systemic Therapy of NSCLC. <i>Journal of Thoracic Oncology</i> , 2014, 9, 144-153.	0.5	83
20	Intratumoral Immunotherapy: From Trial Design to Clinical Practice. <i>Clinical Cancer Research</i> , 2021, 27, 665-679.	3.2	69
21	Prevalence and Clinical Patterns of Ocular Complications Associated With Anti-PD-1/PD-L1 Anticancer Immunotherapy. <i>American Journal of Ophthalmology</i> , 2019, 202, 109-117.	1.7	62
22	Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 468-470.	0.5	56
23	Impact of aging on immune-related adverse events generated by anti-“programmed death (ligand)PD-(L)1 therapies. <i>European Journal of Cancer</i> , 2020, 129, 71-79.	1.3	45
24	Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e67-e67.	0.5	40
25	The 2016“2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study. <i>European Journal of Cancer</i> , 2020, 130, 39-50.	1.3	37
26	Pseudoprogession in Non“Small Cell Lung Cancer upon Immunotherapy: Few Drops in the Ocean?. <i>Journal of Thoracic Oncology</i> , 2019, 14, 328-331.	0.5	31
27	PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon. <i>Cancer Discovery</i> , 2022, 12, 1435-1448.	7.7	28
28	Immune checkpoint inhibitors in advanced nonsmall cell lung cancer. <i>Current Opinion in Oncology</i> , 2015, 27, 108-117.	1.1	26
29	Interventional Radiology for Local Immunotherapy in Oncology. <i>Clinical Cancer Research</i> , 2021, 27, 2698-2705.	3.2	26
30	Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non“Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy. <i>JCO Precision Oncology</i> , 2020, 4, 829-840.	1.5	25
31	Evidence of pseudoprogession in patients treated with PD1/PDL1 antibodies across tumor types. <i>Cancer Medicine</i> , 2020, 9, 2643-2652.	1.3	21
32	Influence of HAART on Alternative Reading Frame Immune Responses over the Course of HIV-1 Infection. <i>PLoS ONE</i> , 2012, 7, e39311.	1.1	17
33	<p>Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 2505-2512.	1.0	17
34	Neurological complications induced by immune checkpoint inhibitors: a comprehensive descriptive case-series unravelling high risk of long-term sequelae. <i>Brain Communications</i> , 2021, 3, fcab220.	1.5	16
35	Transcriptional Errors in Human Immunodeficiency Virus Type 1 Generate Targets for T-Cell Responses. <i>Vaccine Journal</i> , 2009, 16, 1369-1371.	3.2	14
36	Managing Hyperprogressive Disease in the Era of Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade: A Case Discussion and Review of the Literature. <i>Oncologist</i> , 2020, 25, 369-374.	1.9	13

#	ARTICLE	IF	CITATIONS
37	Patterns of progression in patients treated for immuno-oncology antibodies combination. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 221-232.	2.0	12
38	Human Endogenous Retrovirus Expression Is Upregulated in the Breast Cancer Microenvironment of HIV Infected Women: A Pilot Study. <i>Frontiers in Oncology</i> , 2020, 10, 553983.	1.3	11
39	Understanding genetic determinants of resistance to immune checkpoint blockers. <i>Seminars in Cancer Biology</i> , 2020, 65, 123-139.	4.3	9
40	Feasibility, safety and efficacy of human intra-tumoral immuno-therapy. Gustave Roussy's initial experience with its first 100 patients. <i>European Journal of Cancer</i> , 2022, 172, 1-12.	1.3	7
41	T Cells Target APOBEC3 Proteins in Human Immunodeficiency Virus Type 1-Infected Humans and Simian Immunodeficiency Virus-Infected Indian Rhesus Macaques. <i>Journal of Virology</i> , 2013, 87, 6073-6080.	1.5	6
42	Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicities. <i>European Journal of Cancer</i> , 2021, 157, 383-390.	1.3	6
43	A Phase 1 Study Evaluating BI 765063, a First in Class Selective Myeloid Sirpa Inhibitor, As Stand-Alone and in Combination with BI 754091, a Programmed Death-1 (PD-1) Inhibitor, in Patients with Advanced Solid Tumours. <i>Blood</i> , 2019, 134, 1040-1040.	0.6	6
44	Reply to: "Incidence of grade 3-4 liver injury under immune checkpoints inhibitors: A retrospective study". <i>Journal of Hepatology</i> , 2018, 69, 1397-1398.	1.8	2
45	Reply to: "Immune-related hepatitis with immunotherapy: Are corticosteroids always needed?". <i>Journal of Hepatology</i> , 2018, 69, 550-551.	1.8	2
46	Reply to: "Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies?". <i>Journal of Hepatology</i> , 2019, 70, 566-567.	1.8	2
47	Hyperprogression upon immunotherapy: A chance for (hyper-)progress. <i>European Journal of Cancer</i> , 2020, 126, 139-140.	1.3	2
48	Sustained cancer clinical trial activity in a French hospital during the first wave of the COVID-19 pandemic. <i>Cancer Cell</i> , 2021, 39, 1039-1041.	7.7	2
49	Hematological adverse events related to the immune system with immune checkpoint inhibitors, a comprehensive review as a basis for clinical guidelines. <i>Hematologie</i> , 2018, 24, 183-193.	0.0	0
50	Reply to: "Mortality due to immunotherapy related hepatitis". <i>Journal of Hepatology</i> , 2018, 69, 978-979.	1.8	0
51	Relapsed and refractory classical Hodgkin lymphoma: could virotherapy help solve the equation?. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 3502-3510.	1.4	0
52	Immunological Cytopenias Induced By Anti-Programmed Cell Death (ligand) 1 Antibodies. <i>Blood</i> , 2018, 132, 2412-2412.	0.6	0
53	Outcomes of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Included in Phase I Clinical Trials. <i>Blood</i> , 2018, 132, 2992-2992.	0.6	0